Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Mesothelin-induced lysosomal biogenesis sustains neutrophil longevity to drive brain metastasis.

Created on 28 Oct 2026

Authors

Xiaoxia Chen, Chengtao Dong, Yinglun Wang, Tianyu Yun, Li Wang, Ruizhe Chen, Yuchen Shen, Caiting Tang, Yuxuan Xie, Kunlin Zeng, Yong Yang, Zelong Han, Junguo Bu, Shangbiao Li, Aidong Zhou

Published in

Cell reports. Volume 45. Issue 11. Pages 118181. Oct 27, 2026. Epub Oct 27, 2026.

Abstract

Tumor-associated neutrophil (TAN) enrichment is a defining feature and driving force of brain metastases (BrMs), a leading cause of death in solid tumors. Yet, the mechanisms governing TAN enrichment in BrM remains undefined. Herein, we demonstrate that BrM cell-derived shed soluble mesothelin (sMSLN) critically prolongs neutrophil survival to facilitate tumor cell colonization and outgrowth in the brain. Specifically, sMSLN binds to toll-like receptor 4 (TLR4) on neutrophil to activate the JAK2-STAT3 pathway. This activation promotes lysosomal biogenesis and function, reducing cellular reactive oxygen species (ROS) and inhibiting neutrophil apoptosis. Neutrophil depletion or TLR4-STAT3 blockade abrogates sMSLN-induced BrM progression. Targeting MSLN with Anetumab effectively reduces TAN enrichment, and combining this with TLR4 inhibition synergistically suppresses lung cancer BrM. Our findings establish a critical role for tumor cell-derived sMSLN in sustaining neutrophil longevity and driving BrM, highlighting the sMSLN-TLR4 axis as a promising therapeutic target for brain metastatic tumors.

PMID:
42945212
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 72
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement